AstraZeneca’s board scrapped merger talks with Bristol Myers Squibb on Aug. 3, days after reports emerged that the companies were discussing a roughly $400 billion tie-up, according to a report from the Financial Times. The two companies had been in serious talks throughout the spring and summer and were nearing agreement on price, with an announcement targeted for mid-August, according to the report.
Read the full article: How AstraZeneca’s $400B Bristol Myers Deal Fell Apart //
Source: https://www.beckershospitalreview.com/pharmacy/how-astrazenecas-400b-bristol-myers-deal-fell-apart/